Two multicenter efforts unveiled genomic approaches that predict sentinel lymph‑node metastasis risk in melanoma patients and could reduce the need for surgical biopsies. One study led by nine U.S. cancer centers demonstrated that a gene‑expression profile integrated with clinicopathologic features can identify patients at low risk for nodal metastasis. A separate Mayo Clinic collaboration with SkylineDx published a genomic assay in JAMA Surgery showing similar potential to guide clinical decision making. Both teams described external multicenter validation and emphasized that adopting molecular risk stratification could personalize surgical decision pathways. Investigators noted the need for prospective implementation studies and regulatory engagements to move these tests into routine care.